EPOCell Therapeutics

EpoCel Therapeutics is pioneering a breakthrough regenerative cell therapy for chronic kidney disease (CKD) and renal anemia. Our platform uses autologous, EPO-producing cells derived non-invasively from urine, engineered for targeted kidney regeneration. Our lead product, represents a novel paradigm: combining regenerative cell biology with therapeutic erythropoietin production to simultaneously address inflammation, fibrosis, and anemia in CKD. EpoCel stands for scientific excellence, translational focus, and clinical impact – aiming to bring new hope to millions of patients worldwide. 🔹 Mission To restore kidney function and treat renal anemia through innovative, patient-derived regenerative cell therapies. 🔹 Vision A future where chronic kidney disease is no longer a progressive sentence, but a condition treated at its root – with the patient’s own cells.